Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine

被引:10
作者
Chowdhury, Fahima [1 ]
Bhuiyan, Taufiqur Rahman [1 ]
Akter, Afroza [1 ]
Bhuiyan, Md Saruar [1 ]
Khan, Ashraful Islam [1 ]
Tauheed, Imam [1 ]
Ahmed, Tasnuva [1 ]
Ferdous, Jannatul [1 ]
Dash, Pinki [1 ]
Basher, Salima Raiyan [1 ]
Al Hakim [1 ]
Lynch, Julia [2 ]
Kim, Jerome H. [2 ]
Excler, Jean-Louis [2 ]
Kim, Deok Ryun [2 ]
Clemens, John D. [1 ,3 ,4 ]
Qadri, Firdausi [1 ]
机构
[1] Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh
[2] Int Vaccine Inst, Seoul, South Korea
[3] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA
[4] Korea Univ, Sch Med, Seoul, South Korea
基金
比尔及梅琳达.盖茨基金会;
关键词
Oral Cholera Vaccine (OCV); Augmented immune response; Booster dose; Primary dose; Shanchol; ANTIBODY-SECRETING CELL; SUBUNIT-WHOLE-CELL; VIBRIOCIDAL ANTIBODY; DOUBLE-BLIND; B-CELLS; IMMUNOGENICITY; ANTIGEN; SAFETY; PROTECTION; INFECTION;
D O I
10.1016/j.vaccine.2019.12.034
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have earlier reported that a single dose of oral cholera vaccine (OCV) is protective in adults and children >= 5 years of age and sustained for 2 years. We enrolled participants (n = 240) from this study, between March-September 2017, over 3 years after receiving a primary single dose. Immune responses were measured in placebo group (Primary Immunization group: PI) and compared with those who received a single dose (Booster Immunization group: BI). The children were 4 to <5 years, 5 to <18 years and adults >18 years. Blood was collected at day 0 (before vaccination) and after receiving 1st and 2nd doses of OCV. Overall, the BI and PI groups showed vibriocidal antibody response after 1st and 2nd dose of vaccination in all age groups to V. cholerae O1 and O139. Young children in the BI group showed significantly higher vibriocidal antibody response two weeks after receiving the first dose as compared to PI group to LPS. Elevated plasma IgA responses to LPS after the first dose were observed among the BI group compared to the PI group among the young children. Mucosal antibody responses measured in fecal extracts showed similar increases as that of vibriocidal and LPS responses in the BI group. These results suggest a single boosting dose of OCV generated immune response in primed population >5 years of age who had earlier received OCV. However, young children who had received OCV earlier, boosting after a single dose, resulted in increased immune responses compared to the PI group. Further studies are needed to assess protection obtained from different strategies, especially for young children and to determine the numbers of primary and booster doses needed. In addition, more information is needed regarding the optimum interval between primary and booster doses to plan future interventions for cholera control. (C) 2019 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:1753 / 1761
页数:9
相关论文
共 22 条
  • [11] Quantitative and Qualitative Anamnestic Immune Responses to Pneumococcal Conjugate Vaccine in HIV-Infected and HIV-Uninfected Children 5 Years after Vaccination
    Madhi, Shabir A.
    Klugman, Keith P.
    Kuwanda, Locadiah
    Cutland, Clare
    Kaeyhty, Helena
    Adrian, Peter
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (08) : 1168 - 1176
  • [12] Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age
    Johnston, William
    Essink, Brandon
    Kirstein, Judith
    Forleo-Neto, Eduardo
    Percell, Sandra
    Han, Linda
    Keshavan, Pavitra
    Smolenov, Igor
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (01) : E19 - E27
  • [13] Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children &lt; 2 years of age with, or without, a booster vaccination
    Vadrevu, Krishna Mohan
    Raju, Dugyala
    Rani, Sandhya
    Reddy, Siddharth
    Sarangi, Vamshi
    Ella, Raches
    Javvaji, Bhuvaneswara
    Mahantshetty, Niranjana S.
    Battu, Sudhakar
    Levine, Myron M.
    VACCINE, 2021, 39 (45) : 6682 - 6690
  • [14] Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine
    Quiambao, Beatriz
    Peyrani, Paula
    Li, Ping
    Cutler, Mark W.
    Van Der Wielen, Marie
    Perez, John L.
    Webber, Chris
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (06) : 1272 - 1279
  • [15] Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China
    Tang, Xuewen
    Xiao, Yanhui
    Deng, Xuan
    Zhou, Yang
    Chen, Haiping
    Yan, Rui
    Zhu, Yao
    Wang, Shengyi
    Wang, Hui
    Zhu, Xiujuan
    Luo, Linyun
    Liu, Yan
    Yin, Zhiying
    Zhang, Guoping
    Chen, Zhongbing
    Jiang, Jian
    Yang, Xiaoming
    He, Hanqing
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 34
  • [16] The effects of booster vaccination on combined hepatitis A and hepatitis B vaccine in both anti-HBs and anti-HAV negative children 5-15 years after hepatitis B vaccine primary immunization
    Chen, Yongdi
    Gu, Hua
    Cheng, Suyun
    Shen, Lingzhi
    Cui, Fujiang
    Wang, Fuzhen
    Yao, Jun
    Xia, Shichang
    Lv, Huakun
    Liang, Xiaofeng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (04) : 898 - 902
  • [17] Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines
    Vesikari, Timo
    Forsten, Aino
    Bianco, Veronique
    Van der Wielen, Marie
    Miller, Jacqueline M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (12) : E298 - E307
  • [18] Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years
    Trieu, Mai-Chi
    Zhou, Fan
    Lartey, Sarah Larteley
    Sridhar, Saranya
    Mjaaland, Siri
    Cox, Rebecca Jane
    NPJ VACCINES, 2018, 3
  • [19] Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age
    Matsuda, F.
    Chowdhury, M. I.
    Saha, A.
    Asahara, T.
    Nomoto, K.
    Tarique, A. A.
    Ahmed, T.
    Nishibuchi, M.
    Cravioto, A.
    Qadri, F.
    VACCINE, 2011, 29 (10) : 1855 - 1858
  • [20] Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland
    Patrzalek, M.
    Albrecht, P.
    Sobczynski, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (07) : 787 - 792